Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
-
- STATUS
- Recruiting
-
- End date
- Jul 26, 2021
-
- participants needed
- 125
-
- sponsor
- M.D. Anderson Cancer Center
Summary
This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacytidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate and azacytidine may be an effective treatment for myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm.
Description
PRIMARY OBJECTIVES:
I. To determine the efficacy of the combination of RUX (ruxolitinib phosphate) with AZA (azacytidine) in patients with myelofibrosis (MF) (primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocythemia myelofibrosis [PMF, post- PV MF, or post - ET MF]) in achieving objective improvements in disease status.
II. To determine the efficacy of the combination of RUX + AZA in patients with myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (breakpoint cluster region [BCR]-c-abl oncogene 1, non-receptor tyrosine kinase [ABL1] negative: aCML), and myelodysplastic syndromes/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U), in achieving objective improvements in disease status.
SECONDARY OBJECTIVES:
I. To determine the safety of the RUX + AZA combination in patients with MF and MDS/MPN.
TERTIARY OBJECTIVES:
I. To explore time to response (TTR) and duration of response (DOR). II. To explore the effect of the combination on anemia and transfusion dependence in patients with MF and MDS/MPN.
III. To explore the impact of baseline mutational profile on International Working Group (IWG)-Myeloproliferative Neoplasms Research and Treatment (MRT) response and overall survival in patients with MF and MDS/MPN.
IV. To explore the impact of baseline anemia on overall survival in patients with MF and MDS/MPN.
OUTLINE: Patients are assigned to 1 of 2 treatment arms.
ARM I (MF): Patients with MF receive ruxolitinib phosphate orally (PO) twice daily (BID) on days 1-28. Beginning course 4, patients also receive azacytidine subcutaneously (SC) or intravenously (IV) for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
ARM II (MDS/MPN): Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.
After completion of study treatment, patients are followed up for 30 days and up to 5 years.
Details
| Condition | leukemia, Myelosclerosis with myeloid metaplasia, Leukemia (Pediatric), Post Essential Thrombocythemia Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase |
|---|---|
| Treatment | laboratory biomarker analysis, Ruxolitinib (RUX), Azacitidine (AZA), Questionnaires, Questionnaires, Azacitidine, Ruxolitinib Phosphate |
| Clinical Study Identifier | NCT01787487 |
| Sponsor | M.D. Anderson Cancer Center |
| Last Modified on | 26 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer